临时与持久性左心室辅助装置桥接心脏移植的比较
基于美国器官网络数据库,分析2018年10月18日至2020年9月30日期间以临时或持久性左心室辅助装置桥接至心脏移植的成人受者。共纳入1734例,其中持久性装置组1580例(91.1%),临时装置组154例(8.9%)。临时装置组1年生存率有升高趋势但未达统计学显著(94.8% vs 90.1%;p=0.06);风险调整后持久性装置与1年死亡率4倍风险相关(HR 3.96,95%CI 1.42-11.03;p=0.009)。
要点
- 临时装置桥接组1年生存率有升高趋势但未达统计学显著(94.8% vs 90.1%;p=0.06)。
- 风险调整后持久性装置与1年死亡率4倍风险相关(HR 3.96,95%CI 1.42-11.03;p=0.009)。
- 2018年至2021年临时装置桥接使用增加,但持久性装置仍为更常见的桥接策略。
核心结论
- 自2018年分配系统变更以来,临时左心室辅助装置作为心脏移植桥接的使用稳步增加。
- 总体而言,以临时装置桥接的患者1年生存率与持久性装置桥接者相比似乎至少相当。
研究设计与样本
- 查询美国器官网络数据库,识别2018年10月18日至2020年9月30日期间以孤立临时或持久性左心室辅助装置桥接至原位心脏移植的所有成人受者。
- 共分析1734例心脏移植受者,其中1580例(91.1%)以持久性装置桥接,154例(8.9%)以临时装置桥接。
- 主要结局为移植后1年生存率,并建模死亡预测因素,同时检查研究期间左心室辅助装置桥接的国家趋势。
主要发现
- 移植时,临时装置组总胆红素水平更高,移植前静脉正性肌力药物使用和机械通气的比例更高。
- 临时装置组的中位等待名单时间更短。
- 1年时,临时装置组生存率有升高趋势但未达统计学显著(94.8% vs 90.1%;p=0.06)。
- 风险调整后,持久性装置与1年死亡率4倍风险相关(HR 3.96,95%CI 1.42-11.03;p=0.009)。
- 2018年至2021年,临时装置桥接增加,但持久性装置仍为更常见的桥接策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since the revision of the United States heart allocation system, increasing use of mechanical circulatory support has been observed as a means to support acutely ill patients. We sought to compare outcomes between patients bridged to orthotopic heart transplantation (OHT) with either temporary (t-LVAD) or durable left ventricular assist devises (d-LVAD) under the revised system. METHODS: The United States Organ Network database was queried to identify all adult OHT recipients who were bridged to transplant with either an isolated t-LVAD or d-LVAD from 10/18/2018 to 9/30/2020. The primary outcome was 1-year post-transplant survival. Predictors of mortality were also modeled, and national trends of LVAD bridging were examined across the study period. RESULTS: About 1,734 OHT recipients were analyzed, 1,580 (91.1%) bridged with d-LVAD and 154 (8.9%) bridged with t-LVAD. At transplant, the t-LVAD cohort had higher total bilirubin levels and greater prevalence of pre-transplant intravenous inotrope usage and mechanical ventilation. Median waitlist time was also shorter for t-LVAD. At 1 year, there was a non-significant trend of increased survival in the t-LVAD cohort (94.8% vs 90.1%; p = 0.06). After risk adjustment, d-LVAD was associated with a 4-fold hazards for 1-year mortality (hazard ratio 3.96, 95% confidence interval 1.42-11.03; p = 0.009). From 2018 to 2021, t-LVAD bridging increased, though d-LVAD remained a more common bridging strategy. CONCLUSIONS: Since the 2018 allocation change, there has been a steady increase in t-LVAD usage as a bridge to OHT. Overall, patients bridged with these devices appear to have least equivalent 1-year survival compared to those bridged with d-LVAD.
引用
- Hess NR, Hickey GW, Keebler ME, et al. Left ventricular assist device bridging to heart transplantation: Comparison of temporary versus durable support. J Heart Lung Transplant. 2022. PMID: 36182653. doi:10.1016/j.healun.2022.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。